Siklos Now Available in 100mg Scored Tablets
Siklos is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in children with sickle cell anemia.
Sickle Cell Disease
Medical Marijuana Tied to Fewer Admissions in Sickle Cell Disease
But no change in opioid use observed for those receiving medical marijuana certification
Novel Pyruvate Kinase Activator Gets Orphan Drug Status for Sickle Cell Disease
The Food and Drug Administration (FDA) has granted Orphan Drug designation to FT-4202 (FORMA Therapeutics) for the treatment of sickle cell disease (SCD).
New Drug Product: Oxbryta
This slideshow shows drug information for Oxbryta. Click here for the complete Oxbryta monograph.
Gene Therapy for Sickle Cell Disease Receives Orphan Drug Designation
The Food and Drug Administration has granted Orphan Drug designation to ARU-1801 (Aruvant) for the treatment of sickle cell disease.
MPR Weekly Dose Podcast: Episode 15
Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60’s; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.
First-of-Its-Kind Therapy Approved for Sickle Cell Disease
The FDA has approved Oxbryta (voxelotor; Global Blood Therapeutics) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
MPR Weekly Dose Podcast: Episode 14
This week on the Pod we talk about the FDA Advisory Committee vote on Vascepa; Antibiotic resistant threats; New contact lenses approved to slow myopia in children; A new treatment for sickle cell disease; And an approval for the rare disease, acute hepatic porphyria.
Adakveo Approved for Sickle Cell Disease
The FDA has approved Adakveo (crizanlizumab-tmca; Novartis) to reduce the frequency of vaso-occlusive crisis (VOC) in patients aged ≥16 years with sickle cell disease.
Study Investigating Rivipansel in Patients With Sickle Cell Disease Misses End Points
The primary end point was time to readiness for discharge, defined as the difference between the readiness-for-discharge date and time and the start date and time of the first infusion of study drug.
